Drug profile · INN
diphemanil methylsulfate
PRANTAL
diphemanil methylsulfate (PRANTAL) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — diphemanil methylsulfate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
diphemanil methylsulfate (PRANTAL) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M1 antagonist
Primary target: Muscarinic acetylcholine receptor M1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is diphemanil methylsulfate?
diphemanil methylsulfate (PRANTAL) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for diphemanil methylsulfate?
PRANTAL is a marketed brand name for diphemanil methylsulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of diphemanil methylsulfate?
diphemanil methylsulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.